Without targeted policy interventions, such as expanded insurance coverage or income-based subsidy programs, the benefits of GLP-1 medications may continue to accrue disproportionately to higher-income populations, leaving behind the very communities most affected by obesity
Reasons for Discontinuation Of GLP1 Receptor Agonists: Data From a Real-World Cross-Sectional Survey of Physicians and Their Patients With Type 2 Diabetes
These foods provide essential nutrients like biotin, zinc, and iron, which are critical for strong and healthy hair
FDA-approved GLP-1 drugs like Wegovy are explicitly cleared for weight loss in people with a BMI over 30 and for those with a BMI below 27 who have weight-related comorbidities like diabetes, hypertension, high cholesterol, and sleep apnea
DSIP does not replace evidence-based insomnia treatment, sleep apnea evaluation, mental health care, medication review, or behavioral sleep therapy